1. DISTINGUISHED PRESENTERS INCLUDE:
CONFERENCE SPONSORS:
www.q1productions.com
STRENGTHENING PATIENT ADVOCACY RELATIONS
Advancing Patient Advocacy through Progressive Communication and Collaboration on Value &
Innovation, Impactful Coalition & Public Policy Influence and Tackling Patient Access Hurdles in a
Shifting Healthcare Environment While Defining Patient Centricity in Organizational Development
JULY 14-15, 2016 | BALTIMORE, MD
5th Annual
Greg Chesmore
Executive Director, State Government
Relations
CELGENE
Angela Wilson
Director Advocacy Relations
GENENTECH
Geraldine Carroll
Director, Advocacy Relations
BIOGEN IDEC
Mary Frances Harmon
Head of Global Patient Advocacy
PTC THERAPEUTICS
David Rintell
Director, Patient Advocacy
GENZYME
Gwendolyn Mayes, JD, MMSc
US Advocacy Relations
BAYER
Fran Kochman
National Director, Advocacy & Alliance
Development
GSK
Kim Mooney
Associate Director, Patient Advocacy
ULTRAGENYX
Jennifer Mills
Director Advocacy Relations
GENENTECH
Fatima Scipione
Senior Director Patient Advocacy
TAKEDA PHARMACEUTICALS
Kristina Broadbelt
Director, Global Patient Advocacy
RAPTOR PHARMACEUTICALS
Kim Isenberg
Director, US Patient Advocacy
BAXALTA, INC.
Seema Kumar
Vice President, Global Health &
Policy Communication
JOHNSON & JOHNSON
Tierney Saccavino
Senior Vice President, Corporate
Communications
ACORDA THERAPEUTICS
Molly Williams
Director, Government Relations, Advocacy
and Professional Affairs
PFIZER
Pamela Bennett
Executive Director, Patient and
Professional Relations
PURDUE PHARMA
Robert Bellucci
Senior Director, Medical Provider Policy
& Advocacy
CELGENE
PHARMACEUTICAL INDUSTRY:
PATIENT GROUPS:
INDUSTRY THOUGHT LEADERS:
Meghan Buzby, M.B.A.
Senior Director of Advocacy
INTERNATIONAL MYELOMA
FOUNDATION
Randi Clites
Advocacy Coordinator
OHIO BLEEDING DISORDER COUNCIL
James Valentine
Associate
HYMAN, PHELPS & MCNAMARA
Team Member
CTTI
Mary E. Cobb
Rare Disease Patient Advocate
PATIENTVUE
Grace Whiting JD
Director, Communications & Coalitions
NATIONAL ALLIANCE FOR CAREGIVING
Patrick Stone
Associate Dir., State Government
Relations
NATIONAL PSORIASIS FOUNDATION
Jonas de Souza, MD
Assistant Professor of Medicine
Section of Hematology/Oncology
THE UNIVERSITY OF CHICAGO
MEDICAL CENTER
Michael Ybarra, M.D.
Sr. Director of Alliance Development
PHRMA
Kevin J. Fowler
Kidney Advocacy Committee
NATIONAL KIDNEY FOUNDATION
Patient Family Partnership Council
KIDNEY HEALTH INITIATIVE
TBD
COPD FOUNDATION
Jean Campbell
Principal
JF CAMPBELL CONSULTANTS
Kathy Gram
Vice President Patient Advocacy
SNOW COMPANIES

2. Fran Kochman
National Director, Advocacy &
Alliance Development
GSK
Years in the industry: Celebrating 30 years with GSK
What motivated you to participate in Q1’s 5th Annual
Advocacy event?
I like the overall theme which extends the role of advocates and advocacy
organizations to advance their capabilities to drive decision making and en-
sure the patient voice is heard, and valued, and included. I think the topics to
be presented are important in ensuring the ways of working between stake-
holders is transparent and accepted as mutually respectful and aligned.
Why do you find the role of patient advocacy to be important?
It is the voice of the patient – told themselves, or through an advocacy or-
ganization - that can educate others and drive decision making which im-
proves disease outcomes and a patients quality of care and life.
Why do you find your particular topic to be of importance to this
years’ agenda?
There are different times to engage patients during treatment development
and delivery. Just as important, are the different times and ways to engage
patients throughout their disease journey, which in many cases never ends,
in a way to better understand what is valuable to them and how they can
maximize their experience, and build their capabilities to drive change.
Grace Whiting JD
Director, Communications & Coalitions
NATIONAL ALLIANCE FOR
CAREGIVING
Years in the industry: 5 years
What motivated you to participate in Q1’s 5th Annual
Advocacy event?
The Q1 Event always has good conversation and provides an “inside look”
-
porate colleagues. It helps us think through how we can be valuable and
meaningful partners with others in the healthcare space.
Why do you find the role of patient advocacy to be important?
Better clinical outcomes and lower health system costs go hand in hand
with addressing patient needs and wants. Great health requires people to
change their whole lives, and systems have to understand how that patient
peace.
Why do you find your particular topic to be of importance to this
years’ agenda?
It’s important for organizations with different perspectives to communicate
about how they’re tackling healthcare issues - as the saying goes, “many
hands make light work.”
James E. Valentine
Associate
HYMAN, PHELPS, & MCNAMARA
Team Member
CTTI
Why do you find the role of patient advocacy to be important?
Patients and caregivers provide a unique perspective about their disease
and how the experience it that researchers and clinicians cannot bring to the
table. Having patient advocates engaged in the clinical trials enterprise can
help ensure it takes into account these experiences of patients and their
development programs, leading to a greater number of treatment options
coming to market.
Why do you find your particular topic to be of importance to this
years’ agenda?
In my work with the Clinical Trials Transformation Invitiative, in looking to
identify best practices for engagement between clinical research sponsors
-
rier to effective engagement. However, in the United States, our legal and
regulatory framework provides a great deal of opportunity for engagement
with patients and patient groups. In fact, FDA encourages industry and the
patient community to work more collaboratively. Having an understanding
of this framework can help all stakeholders ensure compliant engagement
that will still further the mutual interests: the development of safe and ef-
fective treatments.
Kevin J. Fowler
Kidney Advocacy Committee
NATIONAL KIDNEY FOUNDATION
Patient Family Partnership Council
KIDNEY HEALTH INITIATIVE
Years in the industry: 30 years
What motivated you to participate in Q1’s 5th Annual
Advocacy event?
I possess a very unique perspective on patient advocacy based upon my
pharma experience in both commercial and R+D organizations combined
with my own patient journey.
Why do you find the role of patient advocacy to be important?
For Life Science and Health Care organizations to adapt to transforming
healthcare, the patient voice must be integrated into their organization.
Why do you find your particular topic to be of importance to this
years’ agenda?
Planning, scheduling, executing, and following up on a patient advisory
board meeting is the foundation for creating the patient voice strategy. On
a personal level, I have gained considerable lessons from my own patient
journey that have enhanced my professional patient advocacy credibility.
STRENGTHENING PATIENT ADVOCACY RELATIONS
JULY 14-15 | BALTIMORE, MD
KEY SPEAKER INTERVIEWS:
500 N. DEARBORN STREET, SUITE 500 CHICAGO, IL 60654 (P) 312.822.8100 (F) 312.602.3834 www.q1productions.com
Years in the industry: 8 years, most of which was spent at
FDA as a patient liaison

3. 7:00 REGISTRATION AND MORNING COFFEE
7:50 WELCOME, OPENING REMARKS & PASSPORT CONTEST INTRO
STRENGTHENING PATIENT ADVOCACY RELATIONS
DAY ONE | THURSDAY, JULY 14
CASE STUDY TWO:
• Determining successful relationships without metrics
• Pragmatic approaches to quantifying success
• Providing ROI through soft skills and relationships
David Rintell, Director, Patient Advocacy, GENZYME
12:30 LUNCHEON FOR ALL SPEAKERS, SPONSORS AND ATTENDEES
1:45 PANEL DISCUSSION: GOING BEYOND TREATMENT TO ENGAGE
PATIENTS
Pharmaceutical and biotech companies are looking to partner with advocacy
-
of patient advocacy as it allows pharmaceutical companies to build deeper rela-
tionships with patients through understanding the physiological and emotional
effects of disease on both the patient and care giver. Through round table discus-
sion, attendees will explore innovative ways to engage patients that go beyond
therapy, enhancing patient interaction and fostering enriched relationships.
MODERATOR: HEALTH ADVOCACY STRATEGIES
Grace Whiting JD, Director, Communications & Coalitions
NATIONAL ALLIANCE FOR CAREGIVING
Robert Bellucci, Senior Director, Medical Provider Policy & Advocacy
CELGENE
Meghan Buzby, M.B.A., Senior Director of Advocacy,
INTERNATIONAL MYELOMA FOUNDATION
Fran Kochman, National Director, Advocacy & Alliance Development
GSK
BREAKOUT WORKSHOP
3:30 COFFEE & NETWORKING BREAK
4:00 NAVIGATING COMPLIANT COLLABORATIONS BETWEEN PHARMA
AND PATIENT SUPPORT GROUPS
This workshop provides attendees with a unique opportunity to assess knowl-
edge related to compliance as it impact pharmaceutical patient Advocacy ef-
forts in an interactive and engaging platform. Through open and transparent di-
alogue, attendees will have an opportunity to address common challenges and
gain suggested best practices surrounding compliant interactions and strata-
gems with patients and advocacy groups. Workshop participants will delve into
real-life scenarios, providing a unique opportunity for discussion and debate.
• Working with legal/compliance teams to ensure compliance procedures
• Safeguard compliant conversations when working with PAGs
• Best practices in collaborating on promotional materials
Robert Bellucci, Sr. Director, Medical Provider Policy & Advocacy
CELGENE
Mary E. Cobb, Rare Disease Patient Advocate
PATIENTVUE
INTERACTIVE WORKSHOP & GROUP POLLING
8:00 ACHIEVING AUTHENTIC PATIENT CENTRICITY IN AN EVOLVING
HEALTHCARE LANDSCAPE
There is no question the paradigm has shifted in the healthcare industry, with
a progressive focus on patient centricity as health outcomes and quality of care
become a heightened factor in pursuit of successful and effective healthcare.
While this is a growing “buzz word” throughout the industry, enormous ambi-
authentic patient centric business model which includes the patient at the cen-
ter. Through an interactive group workshop and polling activity, attendees will
used to bring patient centricity to reality and develop tools needed to support
advocacy goals for years to come.
• Teach patient centricity to improve collaboration
• Connect patient centricity with company goals
• Utilizing metrics to measure success in patient centricity
Pam Bennett, Executive Director, Patient and Professional Relations
PURDUE PHARMA
8:45 ADVANCING THE ROLE OF ADVOCACY TO EVOLVE WITH A
DYNAMIC HEALTHCARE ENVIRONMENT
An evolving, complex and dynamic role, advocacy executives are responsible
for critical functions within a pharmaceutical company. It has been suggested
by advocacy professionals across the industry that the role of patient advocacy
can effectively lie within a multitude of departments and the more pressing
healthcare models. A thorough and strategic plan is fundamental to the suc-
cess and retention of top performing advocacy executives.
• Development paths for patient advocacy professionals
• Growth from corporate strategy standpoint
• Examine historic path of advocacy role
• Identifying advocacy goals as healthcare continues to shift
Mary Frances Harmon, Head of Global Patient Advocacy, PTC THERAPEUTICS
2:30 LEGAL REVIEW OF TRENDS IN REGULATIONS AFFECTING ADVOCACY
As pharmaceutical and biotech companies continue to build advantageous,
innovative relationships with patient groups, ensuring compliant interaction
during collaboration is a continued challenge, given the evolving regulatory and
compliance frameworks. Advocacy executives are faced with multiple compli-
ance concerns from off-label use of therapies and the promotion of products
advocacy professionals have a thorough understanding of compliant bound-
• Trends in legal repercussions on anti-kickback in partnerships
• Review funding and promotional regulations for advocacy
• Enhanced HIPPA regulations and the effects on patient information
• Shared advocacy practices that adhere to regulatory guidelines
Fatima Scipione, Sr. Director Patient Advocacy
TAKEDA PHARMACEUTICALS
James Valentine, Associate
HYMAN, PHELPS & MCNAMARA
Team Member
CTTI
11:30 MEASURING SUCCESS: TECHNIQUES USED IN BENCHMARKING
ADVOCACY RELATIONSHIPS
Measuring the impact and value of patient advocacy activities is of tremendous
importance as executives work to continue providing high level support to pa-
tients while also driving value and return to the corporation. While qualifying
and quantifying relationships is seen as a critical component to some advocacy
executives when evaluating success, other organizations view relationships as
to do so can be a demanding task for even the most experienced advocacy
executives. Two varying viewpoints will allow attendees to explore differing ap-
proaches to measuring success.
CASE STUDY ONE:
• Calculating internal effectiveness across advocacy platforms
• Attaching measurable outcomes to relationships
• Providing ROI of advocacy efforts through measurable outcomes
Angela Wilson, Director Advocacy Relations, GENENTECH
9:30 THE THREE R’S OF PATIENT ENGAGEMENT: REPUTATION,
RESPONSIBILITY, RELATIONSHIP
Ever since medicine departed from a paternalistic model of diagnosis & treat-
ment, in which doctors prescribed & patients complied, patients have been de-
manding less third-party advocacy and more direct engagement with providers
and other healthcare stakeholders. Life science companies embracing patient
engagement should be cognizant of three key success factors: reputation, re-
sponsibility, and relationship. Kathy Gram will explore these three factors, draw-
ing on public & exclusive empirical evidence and venturing into industry hot top-
ics such as patient access, multicultural engagement, & sustained outreach.
Kathy Gram, Vice President Patient Advocacy, SNOW COMPANIES
10:15 COFFEE AND NETWORKING BREAK
10:45 PANEL DISCUSSION: ALIGNING ADVOCACY EFFORTS INTERNALLY
TO ATTAIN DESIRED RELATIONSHIPS
Across the life sciences industry, responsibility for patient advocacy and out-
reach are often delegated to varied departments within corporations, depen-
dent upon the corporate structure, goals of the organization, and alignment
of goals with advocacy programs. In order to ultimately support patients and
caregivers, as well as create awareness for treatments, corporations must
thoughtfully align advocacy priorities with internal corporate strategy, estab-
lishing a bridge across the organization, incorporating the needs of groups in-
cluding marketing, public relations, patient outreach and even clinical research.
Through aligning advocacy with corporate priorities, teams will strengthen rela-
tionships across corporations, achieving targets and supporting patients in the
most effective manner possible.
• Assessment of pain points and gaps in alignment
• Evaluate patient groups perspective for communication
• Implement best practices to align internal efforts
Tierney Saccavino, ACORDA THERAPEUTICS
Geraldine Carroll, BIOGEN
Kristina Broadbelt, RAPTOR PHARMACEUTICALS
5:00 PATIENT ACCESS: OPTIMIZING ADVOCACY RELATIONSHIPS TO
IMPROVE ACCESS
developing strategies to overcome access hurdles. From challenges to patient
access in a new regulatory environment to access through patient assistance
programs and expanded access, uncovering strategies on advocacy’s role to
overcome access challenges are key to ensure both pharma companies and
patient groups have plans in place to assist patients. Through a case study pre-
sentation highlighting advocacy coalition and access support, advocacy execu-
tives will have an unparalleled opportunity to discuss access concerns and solu-
tions giving them the information they need to directly impact access strategies.
Greg Chesmore, Executive Director, State Government Relations
CELGENE
Patrick Stone, Associate Director, State Government Relations
NATIONAL PSORIASIS FOUNDATION
5:45 CONCLUSION OF DAY ONE SESSIONS

4. 7:30 REGISTRATION AND MORNING COFFEE
7:50 OPENING REMARKS
STRENGTHENING PATIENT ADVOCACY RELATIONS
DAY TWO | FRIDAY, JULY 15
DISEASE STATE BREAKOUT GROUPS
ACADEMIC INSIGHT & PATIENT PERSPECTIVE
2:30 BEST PRACTICES & LESSONS LEARNED IN ESTABLISHING
COALITIONS
Conference attendees will break into groups to discuss best practices and
lessons learned in constructing coalitions throughout the pharma and biotech
space. The breakout sessions will be facilitated by speakers and conference
attendees representing different disease states. The topics for discussion may
include but are not limited to: rare disease, oncology, chronic illness, care-giv-
ing, and other disease states.
LEARNING OBJECTIVES:
• Action and metrics to measure group success
• Leveraging resources to work together to reach new patients
• Bringing together groups that may not be prone to working together
• Collaborating as a disease state to ensure access
8:00 UNCOVERING ACADEMIC INSIGHT AND THE PATIENT PERSPECTIVE
ON THERAPEUTIC COST & INNOVATION
PART ONE: ACADEMIC INSIGHT: UNDERSTANDING THE PHYSICAL AND
EMOTIONAL TOLL OF THERAPEUTIC COST ON PATIENTS
• Impact on caregivers and family
• Key considerations for advocacy
Jonas de Souza, MD, Assistant Professor of Medicine Section of Hematology/
Oncology, THE UNIVERSITY OF CHICAGO MEDICAL CENTER
PART TWO: PATIENT PERSPECTIVE: UNCOVER THE PATIENT VIEW ON
PRICING AND INNOVATION
Direct interaction with people who are living with chronic illness or terminal
disease offers unique insight into how a patients’ disease impacts their lives.
Uncovering thought processes which take place when a patient is grappling
with survival after diagnoses of a rare disease or facing a lifetime of chronic
-
sisting of patients, patient groups and academia, advocacy executives will have
the unique opportunity to openly discuss the top concerns facing the patient
community today.
Kevin J. Fowler, Kidney Advocacy Committee
NATIONAL KIDNEY FOUNDATION
Patient Family Partnership Council, KIDNEY HEALTH INITIATIVE
Sarah Cassidy, Director, Marketing & Patient Outreach
CANCER HOPE NETWORK
9:00 CASE STUDY: POSITIONING MESSAGES TO CONVEY THE VALUE OF
PRICE & INNOVATION
Value and price are top of mind as many pharmaceutical organizations are be-
ing scrutinized for the mounting cost of drugs that is potentially limiting access
to therapies. Patients, caregivers and patient groups alike are becoming in-
creasingly weary of pharmaceutical companies as negative media around fund-
ing, collaboration and the cost of therapies continues to gain public interest.
Uncovering unique messaging techniques that resonate with patients as well as
transparency best practices can assist patient groups and pharma companies
in their quest to reduce the negative spotlight around cost of therapies.
• Communicate and convey the cost of innovation
• Enhance public message on collaboration with patient groups and pharma
• Partnerships with patient groups to educate public on innovation
Michael Ybarra, M.D., Sr. Director of Alliance Development, PhRMA
3:30 COFFEE & NETWORKING BREAK
3:45 EXPLORING NEW FRONTIERS OF ACCESSING PATIENT
COMMUNITIES THROUGH SOCIAL MEDIA
With access to a wide-range of clinical data, health information and an avenue
to be heard, social media has become an essential function for empowering
the patient voice. Now, more than ever, patients are using social media to
share information on the patient journey as well as seek advice on diagnoses
and treatment. Pharmaceutical organizations often use the fear of regulations
as a reason to not actively participate; limiting the ability to enhance online
advocacy efforts. As social media continues as a primary patient resource it
is necessary for advocacy professionals to enhance two-way communication,
engagement and open dialogue with the patient community.
• Compliant use of social media as an avenue for advocacy
• Best practices in utilizing disease state websites vs product promotion
• The role of social media monitoring within organization
• Traditional vs. earned media: breaking through social media clutter
TBD, COPD FOUNDATION
4:30 DEVELOPMENT OF A GLOBAL MINDSET TO ENHANCE
INTERNATIONAL ADVOCACY RELATIONS
As advocacy operations expand globally, with a particular focus on new markets
such as Latin America and Asia, further obstacles are formed for advocacy pro-
fessionals. Considering differing cultural practices and advocacy efforts that
certify positive relationships as well as a deep understanding of company goals
worldwide. This can be particularly challenging as considering the differing lan-
guages, customs, and regulations is a tremendous responsibility. With expan-
sion happening every day, it is necessary for advocacy professionals to develop
a global mindset when fostering advocacy relations internationally.
• Adapting advocacy structures globally
• Developing diverse cultural advocacy groups
• Alignment of global advocacy with overall mission
Seema Kumar
Vice President, Global Health & Policy Communication
JOHNSON & JOHNSON
Tom Croce
Head, Global Patient Advocacy
SHIRE
5:15 CONCLUSION OF CONFERENCE ACTIVITIES
12:30 LUNCHEON FOR ALL SPEAKERS, SPONSORS AND ATTENDEES
1:30 PARTNERING WITH ADVOCACY GROUPS ON PATIENT-CENTRIC
PUBLIC POLICY INITIATIVES
Patient advocacy in the life science space has made major headway in re-
cent years fostering vital relationships with patients, caregivers, and the dis-
to expand, it is essential to have legislative support, working with lawmakers
and lobbyist to gain backing for programs which initiate change. Case study
examples will assist advocacy professionals in uncovering strategies to en-
gage and partner with patient organizations as well as patients individually to
achieve public policy goals.
• Best practices in organizing legislative advocacy
• Effective way to develop advocacy champions
• Advocacy at state and regional level
• Global public policy concerns and partnership
CASE STUDY ONE:
Randi Clites
Advocacy Coordinator
OHIO BLEEDING DISORDERS COUNCIL
Kim Isenberg
Director, US Patient Advocacy
BAXALTA, INC.
Molly Williams
Director, Government Relations, Advocacy & Professional Affairs
PFIZER
CASE STUDY TWO:
Gwendolyn Mayes, JD, MMSc
US Advocacy Relations
BAYER
9:45 HEALTH ADVOCACY STRATEGIES CASE STUDY
10:30 COFFEE & NETWORKING BREAK
11:00 PANEL DISCUSSION: BUILDING ADVISORY COMMITTEES TO
ENHANCE INTEGRATION OF PATIENT VOICE
Understanding the patients’ needs is a critical component in providing a supe-
rior level of support to enhance advocacy efforts. As pharma and biotech com-
panies look to elevate the patient voice, developing advocacy advisory commit-
tees has become a critical function to engage with patients, stakeholders and
advocacy groups alike. From the initial stages of the preliminary who, what and
when to the utilization of the information obtained from committee meetings,
high-level panel discussion will allow advocacy professionals to explore unique
approaches in developing successful advocacy advisory committees.
• Considerations when developing advisory committees
- Initiation of committee
- Setting committee goals
- Ensuring compliance
• Applying the voice of the customer to advocacy strategies
• Altering advocacy approaches based on feedback
• Considerations to utilize committee throughout organization
Kim Mooney, ULTRAGENYX
Jean Campbell, JF CAMPBELL CONSULTANTS
Angela Wilson, GENENTECH
Kevin J. Fowler, NATIONAL KIDNEY FOUNDATION
KIDNEY HEALTH INITIATIVE
11:45 ENHANCING CLINICAL TRIALS BY ENGAGING PATIENTS &
ADVOCATES IN RESEARCH & DEVELOPMENT
Patient advocates have earned respect for their work and support in raising
billions of dollars for research and heightening awareness of clinical research
with patients. While innovation and research continues to be a vital part of
healthcare, it is imperative pharma manufacturers and advocacy organizations
look for ways to collaborate on support of clinical research. Unveiling ways in
which pharma and patient groups can support drug development is a critical
function in advancing therapeutic progress and treatment options.
• Bringing the voice of the patient into drug development
• Best practices in clinical trial collaboration
• Legally collaborating with patient groups
Jennifer Mills, Director Advocacy Relations, GENENTECH

5. Senior Manager, Global Patient Relations; ABBVIE
Patient Advocacy & Corporate Relations Specialist; ABIOMED
SVP Corporate Communications; ACORDA THERAPEUTICS
Vice President, Patient Engagement; ALKERMES
SVP & Chief Patient Advocate; AMICUS THERAPEUTICS
Vice President Business Communications & Advocacy; ASTELLAS
Head, External Affairs Strategy & Transformation; ASTRAZENECA
Director, Advocacy & Alliance; ASTRAZENECA
Vice President, Patient Advocacy; BAXALTA
Deputy Director, Advocacy Relations; BAYER
Associate Director, CV Advocacy; BOEHRINGER INGELHIEM
Associate Director Advocacy; BRISTOL-MYERS SQUIBB
Director, Mktng & Patient Outreach; CANCER HOPE NETWORK
CANCERCURE
Senior Patient Support Specialist; CELGENE
Associate Director, Patient Advocacy; CELGENE
Founder & CEO; CULLARI COMMUNICATIONS GROUP
Project Coordinator, Clinical Operations & R&D; CUREMARK LLC
Vice President of Advocacy Strategy; DISCOVERY USA
Vice President of Patient Engagement and Support; DYAX CORP
Director, Patient Engagement; EDWARDS LIFESCIENCES
Director of Advocacy & Professional Relations; ELI LILLY & CO
Senior Director, Oncology Advocacy; EMD SORONO
Director Patient Advocacy; GENENTECH
Patient Advocacy; GENOMIC HEALTH
Associate Director, Patient Advocacy; GENZYME
National Advocacy & Alliance Development; GSK
Vice President Patient Advocacy; GLOBAL GENES
President; GLOBAL HEALTHY LIVING FOUNDATION
VP Strategy & Innovation; HEALTH ADVOCACY STRATEGIES LLC
President and CEO; HEALTH PERSPECTIVES GROUP
Senior Director, Government & Public Affairs; HORIZON PHARMA
Director, Patient Advocacy; INCYTE CORPORATION
Global Head of Patient Advocacy & Public Policy; INSMED
Advocacy Specialist; INVENTIV HEALTHCARE
Research Advocate, Principal; JACK-WHELAN
Director, Policy & Advocacy; JANSSEN
Head, Patient Recruitment & Site Support; JANSSEN R&D
Vice President, Corporate Affairs; JAZZ PHARMACEUTICALS
Director, Health Policy & Advocacy; JOHNSON & JOHNSON
Account Supervisor, Development Coordinator; JPA HEALTH
COO; LUNG CANCER ALLIANCE
Executive Director; LUNG CANCER INITIATIVE
Leader US Advocacy & Professional Affairs; MERCK
Director, Strategic Partnerships; NAC
Senior Patient Engagement Manager; NOVO NORDISK
Advocacy Coordinator; OHIO BLEEDING DISORDER COUNCIL
Founding President & CEO; PPMD
Rare Disease Patient Advocate; PATIENTVUE, LLC
Patient Centered Metrics Lead; PFIZER
Director, Global Patient Advocacy; RAPTOR PHARMACEUTICALS
Vice President of Global Patient Advocacy; SANOFI
Director, US Patient Advocacy; SHIRE
Advocacy and Partnerships; SPECTRUM PHARMACEUTICALS
Counsel, Global Oncology Patient Advocacy; TAKEDA PHARMA
Director, Patient Advocacy; VERTEX PHARMACEUTICALS
500 N. DEARBORN STREET, SUITE 500 CHICAGO, IL 60654 (P) 312.822.8100 (F) 312.602.3834 www.q1productions.com
-
rently working within the patient advocacy relations departments of phar-
maceutical and biotech corporations. Job titles of those executives that
VPs, Directors and managers of:
• Patient Advocacy
• Patient Advocacy Relations
• Patient Advocacy and Professional Relations
• Patient Education
• Patient Communications
• Corporate Communications
• Patient Access Programs
At this time, there are a variety of sponsorship and exhibition opportunities
available for companies wishing to increase their visibility and participation
in the program, ranging from w speaking opportunities through to exhibitor
and documentation sponsors. Organizations most suitable for this type of
exposure provide services and solutions including:
• Case Management Services
• Patient Communications
• Patient Outreach
• Grant Development Support
• Mapping/ Global Assessment of Patient Advocacy Groups (PAGs)
• Development of Models for Ongoing Patient Engagement
• Community Events
STRENGTHENING PATIENT ADVOCACY RELATIONS
JULY 14-15 | BALTIMORE, MD
WHO SHOULD ATTEND: PREVIOUS ATTENDEES INCLUDE:
SPONSORSHIP OPPORTUNITIES:
Q1 Productions designs and develops webinars, training courses, confer-
-
der to provide strategic and timely information. Through a rigid production
process focused on end-user research and design, our team is able to un-
derstand the immediate business concerns of today’s leading executives.
Whether focusing on new or pending legislative issues, enhanced business
programs provide solutions to the urgent needs of our attendees.
ABOUT THE ORGANIZERS: